Effectiveness in Switching from Antipsychotic Polypharmacy to Monotherapy in Patients with Schizophrenia: A Case Series
10.9758/cpn.2020.18.1.159
- Author:
Hiroyuki KAMEI
1
;
Hanae YAMADA
;
Masakazu HATANO
;
Manako HANYA
;
Shigeki YAMADA
;
Nakao IWATA
Author Information
1. Departments of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
- Publication Type:Case Report
- From:Clinical Psychopharmacology and Neuroscience
2020;18(1):159-163
- CountryRepublic of Korea
- Language:0
-
Abstract:
In Japan, drug therapy for schizophrenia is characterized by high-dose antipsychotic polypharmacy, which is an uncommon approach internationally. In this study, we reduced the number of antipsychotic agents in 5 patients using the Safety Correction of High-dose Antipsychotic Polypharmacy (SCAP) method and conducted a survey regarding treatment satisfaction. The switch from polypharmacy to monotherapy was achieved in all patients. There was no deterioration in psychiatric symptoms, and adverse reactions were reduced. Three of the subjects were satisfied with the decrease in the number of antipsychotic agents and dose-reduction. These results suggest that the SCAP method is a safe and useful method that can be applied in a clinical setting.
